- Aileron Therapeutics Inc (NASDAQ:ALRN) has announced initial findings from its ongoing study of ALRN-6924 in healthy volunteers.
- Data were presented at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting.
- The initial findings demonstrated that a 0.3 mg/kg dose of ALRN-6924 was well tolerated.
- It resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis.
- Related Content: Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings.
- Aileron will present final data from the Phase 1b small-cell lung cancer trial and additional data from the healthy volunteer study at the European Society for Medical Oncology (ESMO) Congress.
- Price Action: ALRN shares are down 3.52% at $1.09 during the market session on the last check Friday.
Profound Medical Q1 EPS $(0.40) Beats $(0.43) Estimate, Sales $1.40M Miss $1.70M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 8.11 percent decrease over losses of $(0.37) per share from
